A new route that regulates the signaling pathways induced by extracellular matrix (ECM) has been discovered by an international team of researchers, affiliated with UNIST. This may serve as a new diagnostic marker and therapeutic target in the fight against chronic liver diseases. Chronic liver disease is known as the silent killer, as it shows no obvious symptoms until the disease has progressed to an advanced stage. Therefore, making a proper diagnosis in the early stage of disease progression can be a clinical challenge. Led by Professor Jiyoung Park in the School of Life Sciences at UNIST, the research team has discovered that endotrophin (ETP) plays a crucial role in producing a pathological microenvironment in liver tissues of chronic liver disease. ETP is a marker of collagen type VI (COL6) formation, known as the link between obesity and cancer. ‘ETP may be developed as a target substance for a specific therapeutic agent for treating patients with chronic liver disease.’ "ETP levels in adipose tissues are elevated in obesity or diabetes and are associated with adipose tissue fibrosis, inflammation, and angiogenesis, leading to metabolic dysfunction in adipose tissues and systemic insulin resistance," says Professor Park who first discovered ETP in 2012. "Through the identification of the correlation between ETP and chronic liver disease, this study opened new doors in the fight against liver diseases." The study reveals ETP plays an important role in the interaction between 'hepatocytes' and 'non-parenchymal cells' in the progression of liver disease, as follows: ? the signaling pathways from ETP kills the hepatocytes, ? the substances from the dead hepatocytes interact with the hepatocytes, ? cause inflammation and make the liver hard. Finally, if the vicious cycle that leads to 'apoptosis - fibrosis - inflammation' continues, and ? chronic liver disease and liver cancer also occur. In this work, Professor Park and her research team examined the liver tissues from hepatocellular carcinoma (HCC) patients and found that the presence of ETP in tumor-neighboring regions are strongly associated with poor prognosis in HCC patients. Moreover, to assess the direct function of ETP in liver tissues, the research team generated an inducible, liver-specific ETP transgenic mouse (Alb-ETP) and discovered that ETP overexpression is a trigger of liver cancer. "Therapeutic antibodies that inhibit the activity of ETP can be used to break the vicious circle that occurs between liver tissue cells," says Professor Park. "ETP is an extracellular substance that can be easily detected in blood," says Professor Park. "ETP, which appears in the early stage of chronic liver disease, may also serve as an early diagnostic marker." Source: Eurekalert << Patients Recovering From Substance Use Disorder Can Benefit... Brain Cells Likely Involved in Memories of Eating That Influ... >> Recommended Reading HCV Drug Treatment - New Frontiers Hepatitis C is an inflammation of the liver caused by a virus. It is primarily spread through blood and blood products, infected needles and from a pregnant mother to baby. READ MORE Liver Cirrhosis Liver cirrhosis is a chronic liver disease that arises due to alcoholism, hepatitis, or other conditions. Liver failure patients are treated with transplantation. READ MORE Test Your Knowledge on Liver Cancer Primary hepatocellular carcinoma is a cancer that starts in the liver. The liver is the largest organ in the body situated in the upper right quadrant of the abdomen. The liver is also a common site for cancer deposits (metastases) from other ... READ MORE Why is It That Alcohol Use Medications are Not Given to Chronic Liver Disease Patients? Through this study, the researchers are justifying the need for chronic liver disease patients to use Alcohol use medications. Even these patients with the advanced liver disease should receive treatment for the alcohol-use disorder. READ MORE Alcoholic Liver Disease Encyclopedia section of medindia gives general information about Alcoholic Liver Disease. READ MORE Biliary Cirrhosis Biliary cirrhosis occurs due to obstruction to the flow of bile through bile ducts either within the liver or outside the liver. READ MORE Current Treatments for Liver Cancer Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the disease if it is detected early. READ MORE Fatty Liver Disease: A Growing Health Problem in India Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India. READ MORE Hepatitis A Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. Hepatitis A vaccine is available that is 95% effective in preventing the disease. READ MORE Living Donor Liver Transplant: What Are the Risks? The risk of dying as a result of a living donor liver segment removal is between 0.2-2.0%. The risk of morbidity is anywhere between 1.3% (in highly experienced centers) to 60%. READ MORE Milk Thistle Milk Thistle is a resourceful natural plant which has many medicinal benefits. In herbal medication milk thistle is used in cases of liver diseases. READ MORE Wilson's Disease This is a rare inherited systemic disorder of copper metabolism, affecting the liver mainly before other organs. READ MORE Most Popular on Medindia Loram (2 mg) (Lorazepam) Hearing Loss Calculator Diaphragmatic Hernia More News on: Alcoholic Liver DiseaseLiver BiopsyHepatitis ALiverWilson's DiseaseBiliary CirrhosisMilk ThistleCurrent Treatments for Liver CancerFatty Liver Disease: A Growing Health Problem in IndiaLiving Donor Liver Transplant: What Are the Risks?